---
document_datetime: 2023-09-21 19:15:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_en.pdf
document_name: ribavirin-biopartners-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.3033369
conversion_datetime: 2025-12-30 12:59:24.25916
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Name                  | Strength   | Pharmaceutical Form   | Route of Administration   | Packaging              | Package size   |
|-----------------|-----------------------|------------|-----------------------|---------------------------|------------------------|----------------|
| EU/1/10/626/001 | Ribavirin BioPartners | 200 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 84 tablets     |
| EU/1/10/626/002 | Ribavirin BioPartners | 200 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 112 tablets    |
| EU/1/10/626/003 | Ribavirin BioPartners | 200 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 140 tablets    |
| EU/1/10/626/004 | Ribavirin BioPartners | 200 mg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 168 tablets    |

1/1 Medicinal product no longer authorised